- Home
- FRES vs IDYA Comparison
FRES vs IDYA Comparison
Compare FRES & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRES
- IDYA
- Stock Information
- Founded
- FRES 2010
- IDYA 2015
- Country
- FRES United States
- IDYA United States
- Employees
- FRES N/A
- IDYA N/A
- Industry
- FRES Medical Specialities
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- FRES Health Care
- IDYA Health Care
- Exchange
- FRES Nasdaq
- IDYA Nasdaq
- Market Cap
- FRES N/A
- IDYA 2.2B
- IPO Year
- FRES 2020
- IDYA 2019
- Fundamental
- Price
- FRES $1.12
- IDYA $26.23
- Analyst Decision
- FRES
- IDYA Strong Buy
- Analyst Count
- FRES 0
- IDYA 12
- Target Price
- FRES N/A
- IDYA $53.67
- AVG Volume (30 Days)
- FRES 13.5K
- IDYA 1.1M
- Earning Date
- FRES 12-31-2024
- IDYA 11-04-2024
- Dividend Yield
- FRES N/A
- IDYA N/A
- EPS Growth
- FRES N/A
- IDYA N/A
- EPS
- FRES N/A
- IDYA N/A
- Revenue
- FRES $2,341,326.00
- IDYA $3,922,000.00
- Revenue This Year
- FRES N/A
- IDYA N/A
- Revenue Next Year
- FRES N/A
- IDYA $251.89
- P/E Ratio
- FRES N/A
- IDYA N/A
- Revenue Growth
- FRES 94.50
- IDYA N/A
- 52 Week Low
- FRES $0.85
- IDYA $24.48
- 52 Week High
- FRES $9.03
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- FRES 42.61
- IDYA 37.58
- Support Level
- FRES $1.00
- IDYA $24.48
- Resistance Level
- FRES $1.40
- IDYA $27.15
- Average True Range (ATR)
- FRES 0.22
- IDYA 1.34
- MACD
- FRES -0.01
- IDYA -0.11
- Stochastic Oscillator
- FRES 23.55
- IDYA 7.90
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.